Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids

Thorax

Volumn 53, Issue 12, 1998, Pages 1030-1034

  Stirling, R G ^a   Kharitonov, S A ^a   Campbell, D ^a   Robinson, D S ^a   Durham, S R ^a   Chung, K F ^a   Barnes, P J ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Difficult asthma; Exhaled nitric oxide; Inflammatory markers

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; NITRIC OXIDE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE MARKER; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MALE; MORBIDITY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SYMPTOMATOLOGY;

EID: 0031702244     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.12.1030     Document Type: Article

References (36)

1. Chung KF. Management of difficult asthma. Br J Hosp Med 1994;51:80-1.
2. British Thoracic Society. The BTS guidelines on asthma management, 1995: review and position statement. Thorax 1997;52(Suppl 1):S1-21.
3. Lenfant C, Khaltaev N, eds. Global initiative for asthma. Global strategy for asthma management and prevention. NHLBI/ WHO Workshop Report No. 95-3659. Maryland: NIH, 1996.
4. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669-74.
5. Laitinen LA, Laitinen A, Heino M, et al. Eosinophilic airway inflammation during exacerbation of asthma and its treatment with inhaled corticosteroid. Am Rev Respir Dis 1991;143:423-7.
6. Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997;155:1501-8.
7. Ronchi MC, Piragino C, Rosi E, et al. Do sputum eosinophils and ECP relate to the severity of asthma? Eur Respir J 1997;10:1809-13.
8. Antczak A, Nowak D, Shariati B, et al. Increased hydrogen peroxide and thiobarbituric acid-reactive products in expired breath condensate of asthmatic patients. Eur Respir J 1997;10:1235-41.
9. Dohlman AW, Black HR, Royall JA. Expired breath hydrogen peroxide is a marker of acute airway inflammation in pediatric patients with asthma. Am Rev Respir Dis 1993;148:955-60.
10. Ahlstedt S. Clinical application of eosinophilic cationic protein in asthma. Allergy Proc 1995;16:59-62.
11. Roquet A, Hallden G, Ihre E, et al. Eosinophil activity markers in peripheral blood have high predictive value for bronchial hyperreactivity in patients with suspected mild asthma. Allergy 1996;51:482-8.
12. Drazen JM. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997;17:22-30s.
13. Drazen JM, O'Brien J, Sparrow D, et al. Recovery of leukotrienes from the urine of patients with airway obstruction. Am Rev Respir Dis 1992;146:104-8.
14. Kharitonov SA, Yates DH, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343:133-5.
15. Barnes PJ. Exhaled nitric oxide: a new lung function test. Thorax 1996;51:233-7.
16. Hamid Q, Springall JB, Riveros-Moreno P, et al. Induction of nitric oxide synthase in asthma. Lancet 1993;342:1510-3.
17. Massaro AF, Gaston B, Kita D, et al. Expired nitric oxide levels during treatment of acute asthma. Am J Respir Crit Care Med 1995;152:800-3.
18. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 1996;153:454-7.
19. Kharitonov SA, Chung KF, Evans D, et al. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med 1996;153:1773-80.
20. Recomendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Guidelines for the measurement of respiratory function. Respir Med 1994;88:165-94.
21. Kharitonov SA, Alving K, Barnes PJ. ERS Task Force Report. Exhaled and nasal nitric oxide measurement: recommendations. Eur Respir J 1997;10:1683-93.
22. Yates DH, Kharitonov SA, Barnes PJ. Effect of short and long acting inhaled beta agonists on exhaled nitric oxide in asthmatic patients. Eur Respir J 1997;10:1483-8.
23. Djukanovic R, Homeyard S, Gratziou C, et al. The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Am J Respir Crit Care Med 1997; 155:826-32.
24. 2-adrenergic drugs and levels of cortisol and ECP in serum of patients with bronchial asthma. Pneumonol Alergol Pol 1995;63(Suppl 2):76-82.
25. Robinson DS, Bentley AM, Hartnell A, et al. Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function and bronchial responsiveness. Thorax 1993; 48:26-32.
26. Jeffery PK, Wardlaw AJ, Nelson FC, et al. Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperactivity. Am Rev Respir Dis 1989;140: 1745-53.
27. Roche WR, Beasley R, Williams JH, et al. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989;ii:520-4.
28. Wilson JW, Li, X, Pain MCF. The lack of distensibility of asthmatic airways. Am Rev Respir Dis 1993;148:806-9.
29. Brown JP, Greville WH, Finucane KE. Asthma and irreversible airflow obstruction. Thorax 1984;39:131-6.
30. Sont JK, Han J, van Krieken JM, et al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996;51:496-502.
31. Chapman ID, Foster A, Morley J. The relationship between airway inflammation and hyperreactivity of the airways in asthma. Clin Exp Allergy 1993;23:168-71.
32. Lundgren R, Soderberg M, Horstedt P, et al. Morphological studies of bronchial biopsies from asthmatics before and after 10 years treatment with inhaled corticosteroids. Eur Resp J 1988;1:883-9.
33. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987;70: 171-9.
34. Redington AE, Howarth PH. Airway wall remodelling in asthma. Thorax 1997;52:310-2.
35. Woolcock AJ. How does inflammation cause symptoms? Am J Respir Crit Care Med 1996;153:S21-2.
36. Dahl R, Martinatti LC, Boner AL. Monitoring of bronchial asthma. Respir Med 1997;91:581-6.